Know Labs, Inc., a public firm trading on the NYSE American Exchange recently released groundbreaking study results showcasing the significant advancements made in non-invasive blood glucose monitoring. The study titled "Novel data preprocessing techniques in an expanded dataset improve machine learning model accuracy for a non-invasive blood glucose monitor" demonstrates how Know Labs' unique Bio-RFID sensor technology has seen an impressive 11.3% increase in accuracy through algorithm refinement and higher-quality data.
The research involved using the Dexcom G6 CGM to test the capacity of Know Labs' Bio-RFID sensor to continuously quantify blood glucose non-invasively. By employing novel data preprocessing techniques and training a Light Gradient-Boosting Machine (lightGBM) model, the team achieved remarkable results. The model accurately predicted blood glucose values with a Mean Absolute Relative Difference (MARD) of 11.3% in the test set, ensuring a blind evaluation of model performance.
In a subsequent application of the lightGBM machine learning model to data collected from five identical demographic participants, the MARD improved even further, reaching an impressive 12.9%. These achievements indicate the potential of Know Labs' technology to revolutionize blood glucose monitoring by eliminating the need for intrusive and costly lab procedures and offering real-time data at an affordable price.
Know Labs also announced the completion of its Gen 1 prototype in June 2023. This prototype combines the Bio-RFID sensor technology, which has been utilized in clinical research labs for two years, with new environmental and human aspects, resulting in a portable and user-friendly device. The Gen 1 device is currently undergoing rigorous testing to optimize sensor design for data collection, further enhancing its performance and accuracy.
The Company's focus on collecting high-quality, high-resolution data from a diverse participant pool representing various glycemic ranges and testing scenarios is crucial in the development of their algorithms and the optimization of their sensor for broader use. With daily testing of the Gen 1 device and ongoing clinical research, Know Labs aims to validate the algorithm's performance in real-world scenarios, a key milestone before seeking FDA approval for their product.
To reinforce the credibility of their technology, Know Labs intends to refine and externally validate its advancements throughout 2023. The Company aims to add these findings to their already existing peer-reviewed proof, demonstrating their commitment to transparency and scientific rigor.
Know Labs' patented Bio-RFID technology, based on spectroscopy, holds the potential to transform various fields, from wearables to mobile and bench-top devices. With its non-invasive glucose monitor on the horizon, Know Labs is set to disrupt the medical industry by providing a cost-effective, real-time blood glucose monitoring solution. The device's potential to empower individuals to manage their health and improve their quality of life has garnered significant attention.
While the results from the recent study are promising, the Company remains cautious, acknowledging that risks and uncertainties exist. They emphasize the importance of conducting ongoing research and following strict regulatory processes before bringing the product to market.
As Know Labs continues to refine and validate its technology, the potential for an FDA-approved product draws ever closer, promising a game-changing advancement in healthcare technology.
